First adaptive platform trial in ALS could speed development, find new biomarkers

Mass General’s ALS platform trial could find some of the first biomarkers for the disease

An adaptive platform trial for ALS launched by Mass General could find new biomarkers to serve as surrogate endpoints or predictors of response in the pivotal trial and future studies.

Researchers at Massachusetts General Hospital’s Sean M. Healey & AMG Center for ALS believe the time is ripe for the first ever platform trial in amyotrophic lateral sclerosis given the increased understanding of the disease's underlying biology and the more than 100 companies with candidates in preclinical or clinical development for the disease.

“There’s

Read the full 822 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE